Livmarli™ (maralixibat) – New orphan drug approval
September 29, 2021 - Mirum Pharmaceuticals announced the FDA approval of Livmarli (maralixibat), for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.
Download PDF
